Overview Request Sample Pages Request Customization Download PDF
You are viewing: Canada Preimplantation Genetic Testing Market analysis

The Canada Preimplantation Genetic Testing Market was valued at $30.5 Million in 2025 and projected to reach to $43 Million by 2030, representing a compound annual growth rate of 7.1%. Canada's preimplantation genetic testing market is positioned for sustained growth through 2030, supported by advancing diagnostic technologies, increasing fertility clinic adoption, and growing patient demand for reproductive health solutions.

Canada Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Canada Preimplantation Genetic Testing Market Trends and Insights

  • This 7.1% compound annual growth rate reflects increasing adoption of genetic screening technologies among Canadian fertility clinics and growing patient awareness of reproductive health options.
  • Canada's advanced healthcare infrastructure and supportive regulatory environment position the country as a key market for PGT innovation in North America. The Canadian PGT market is driven by rising infertility rates, improved access to assisted reproductive technologies, and heightened demand for genetic disease prevention.
  • Canada's publicly funded healthcare system and private fertility sector collaboration create unique market dynamics that differentiate it from other North American regions.
  • Between 2025 and 2030, Canada is expected to see expanded clinical adoption, increased reimbursement coverage, and growing investment in genetic testing capabilities across major metropolitan centers..

Key Market Statistics

  • CAGR (2025-2030) 7.1% CAGR
  • Market Size, 2025 ~USD 30.5 Million
  • Forecast, 2030 ~USD 43 Million
  • Country Canada

Canada Preimplantation Genetic Testing Market Overview

Market Valuation :

Canada's PGT market is valued at $30.5 million in 2025, with projections reaching $43.0 million by 2030, representing a steady 7.1% CAGR driven by technological adoption and clinical demand.

Healthcare Infrastructure Advantage :

Canada's advanced healthcare system and publicly funded fertility services create a supportive environment for PGT adoption, with increasing integration into assisted reproductive technology (ART) protocols across major fertility centers.

Patient Awareness Growth :

Rising awareness among Canadian patients regarding reproductive health options and genetic screening benefits is driving demand for PGT services, particularly among women aged 35+ seeking advanced diagnostic solutions.

Clinic Expansion Trend :

Canadian fertility clinics are increasingly adopting PGT technologies to enhance treatment outcomes and competitive positioning, with growing investment in genetic testing capabilities across provinces.

Canada Preimplantation Genetic Testing Market Dynamics

  • The 7.1% CAGR reflects a maturing market with strong fundamentals in healthcare infrastructure and clinical integration. Key growth drivers include enhanced patient education initiatives, expanding clinic capabilities, and potential regulatory support for genetic screening in fertility treatments.
  • As Canadian healthcare providers prioritize reproductive outcomes and personalized medicine, PGT adoption is expected to accelerate, particularly in major metropolitan areas with established fertility centers and higher patient accessibility..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Canada's PGT market is valued at $30.5 million in 2025 and is forecast to reach $43.0 million by 2030, representing a 7.1% CAGR.
      • Canada's advanced healthcare infrastructure and regulatory framework support accelerated adoption of preimplantation genetic testing technologies.
      • Rising infertility rates and increased patient demand for genetic disease prevention are primary growth drivers in Canada.
      • Canada's hybrid public-private fertility sector model creates distinct market opportunities compared to other North American regions.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      Canada Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      DIAGNOSTIC LABORATORIES5.766.46.97.488.69.37.8
      FERTILITY CLINICS16.417.11819.220.52223.725.57.2
      HOSPITALS4.14.34.54.755.35.666.2
      OTHER END USERS1.51.51.61.71.81.922.15.4
      TOTAL27.728.930.532.434.637.139.9437.1

      Target Audience

      • Fertility Clinic Operators : Canadian fertility clinics need market data to evaluate PGT service expansion, benchmark adoption rates against peers, and make informed investment decisions in genetic testing infrastructure and staff training.
      • Diagnostic Laboratory Providers : Genetic testing companies and diagnostic labs require Canada-specific market intelligence to assess demand, identify clinic partnerships, and develop localized service offerings aligned with Canadian healthcare standards.
      • Medical Device & Technology Vendors : Equipment manufacturers and software providers need Canadian market insights to understand adoption barriers, regulatory requirements, and clinic procurement patterns for PGT-related technologies and platforms.
      • Healthcare Investors & Consultants : Investment firms and management consultants require detailed Canadian market analysis to evaluate acquisition targets, assess growth potential, and develop strategic recommendations for fertility and reproductive health companies.
      • Healthcare Policy & Regulatory Bodies : Government agencies and healthcare administrators need market data to inform policy decisions, funding allocations, and regulatory frameworks governing PGT services and fertility treatment coverage in Canada.

      Key Companies in the Canada Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Reasons to Buy this Report

      • Market-Specific Sizing & Forecasts : Access precise valuation data for Canada's PGT market ($30.5M in 2025, $43M by 2030) with country-specific CAGR analysis to support investment decisions and business planning in the Canadian fertility sector.
      • Competitive Landscape Intelligence : Understand the competitive positioning of fertility clinics and diagnostic providers operating in Canada, including adoption rates and market share dynamics specific to Canadian provinces and healthcare regions.
      • Regulatory & Healthcare System Insights : Gain detailed knowledge of Canada's healthcare infrastructure, public funding mechanisms, and regulatory environment affecting PGT adoption, enabling compliant market entry and partnership strategies.
      • Patient Demand & Demographic Analysis : Leverage Canada-specific patient demographics, awareness trends, and demand drivers to tailor marketing strategies, service offerings, and clinical protocols for Canadian fertility centers and diagnostic companies.
      • Growth Opportunity Identification : Identify high-potential provinces, clinic segments, and service gaps within Canada's PGT market to prioritize expansion, partnerships, and product development initiatives for maximum ROI.

      Frequently asked questions

      What is the current size of Canada's preimplantation genetic testing market?

      Canada's PGT market was valued at $30.5 million in 2025 and is expected to grow to $43.0 million by 2030.

      What is the projected growth rate for Canada's PGT market?

      Canada's preimplantation genetic testing market is projected to grow at a compound annual growth rate (CAGR) of 7.1% from 2025 to 2030.

      What factors are driving growth in Canada's PGT market?

      Key drivers include rising infertility rates, increased access to assisted reproductive technologies, growing patient awareness of genetic screening, and expanding reimbursement coverage in Canada.

      How does Canada's PGT market compare to other North American regions?

      Canada's market benefits from a unique hybrid public-private healthcare model, advanced regulatory frameworks, and strong fertility clinic infrastructure that differentiate it from the United States and Mexico.

      Which Canadian regions are leading PGT adoption?

      Major metropolitan centers in Canada, including Toronto, Vancouver, and Montreal, are driving PGT adoption through established fertility clinics and advanced genetic testing laboratories.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status